BRAF and lung adenocarcinoma: Previous findings that class II BRAF mutations are oncogenic drivers of lung adenocarcinoma [14] are confirmed in our study, as the Guardant360 test sequences all 20 mutually exclusive oncogenic drivers in lung adenocarcinoma, and in most patients mutations in other known drivers did not co-occur with class II BRAF mutations.